The Numbers Come First
Bank of America is spending $250 million or more each year covering GLP-1 weight-loss drugs for its employees, CEO Brian Moynihan confirmed in a recent CNBC interview. The figure sits inside a broader $2 billion annual wellness package at the $436 billion bank. Employees may cover their own premium or copay, but the institution absorbs the remainder of the bill.
'What we see is a great impact on the employees,' Moynihan said. 'We've always been about mental wellness, physical wellness.'
Moynihan acknowledged a complication most CFOs would flag immediately: some staffers on GLP-1s may not realize the full health benefits until years after they have left Bank of America. He pressed on anyway. 'It's the right thing to do for your teammates,' he said. 'We do it because we want to be the great place to work.'
The CEO pointed to a near-term return that does hold up on a spreadsheet. 'It's lowering near-term incidents of heart issues for people taking, even if they don't have all the attributes,' Moynihan said. 'That's the payback.'
A Market Dividing on Cost
Bank of America's commitment stands out precisely because the broader corporate market is pulling back. More than a quarter of large corporations are tightening GLP-1 coverage criteria in 2026 or 2027, according to a Mercer analysis. Around 11 percent of big employers have dropped — or are planning to drop — weight-loss coverage entirely.
Consulting giant PwC cut GLP-1 coverage for weight-loss purposes earlier this year, citing 'rapidly rising costs,' though it maintained coverage when the drug is prescribed for conditions such as type 2 diabetes. Health services company Cigna stopped covering Wegovy and Zepbound in its own employee health plan this July. HCA Healthcare, which employs hundreds of thousands across its hospital network, pulled weight-loss GLP-1 coverage in January after use on its employee plan surged 90 percent in 2025 alone.
The drugs have gotten cheaper — a starting dose of Wegovy now runs $149 a month, down from $1,600 at its 2021 U.S. launch — but soaring demand and the prospect of indefinite long-term use have put employers in a difficult financial position. Around 11 percent of U.S. adults now take GLP-1 medications for weight loss, up from 3 percent just two years ago, according to a Gallup analysis.
Talent as the Lever
The competitive angle is not subtle. Roughly 30 percent of workers say they would switch jobs to obtain GLP-1 coverage, according to a survey from insurance broker NFP. For a bank competing for talent against technology firms and asset managers, a benefit that moves a third of the workforce is a recruiting argument, not just a wellness gesture.
CEO Times Take
Bank of America's GLP-1 bet is a textbook free-enterprise calculation: deploy capital now, price in future productivity gains, and use a differentiated benefit to win the talent market. Moynihan is not asking Washington for a mandate or a subsidy — he is writing a check and measuring the outcome. That is how private enterprise is supposed to work.
The harder question is whether the math closes when employees depart before the health dividends arrive. Moynihan concedes it may not — and spends the money anyway. Shareholders will eventually render their verdict. For now, the market has not punished the bet, and the CEO's transparency about the trade-off is, at minimum, more honest than most corporate wellness theater.
